Long-Term Debt: PMV Pharma (PMVP)

Brandmark of PMV Pharmaceuticals, Inc (PMVP)

PMV Pharmaceuticals (PMVP) is attracting leading PhDs to restore p53 protein functions, developing innovative methods to combat solid tumors. The business relies on a precision approach to treating genetic defects. This chart of long-term liability costs is fixed at 0.00. Personnel stability is ensured through generous stock options and the hiring of specialized regulatory experts to manage clinical trials.

PMVP (PMV Pharma) Company Long-Term Debt history from 07/04/2022 to 10/30/2026

PMV Pharma - analytical breakdowns and key metrics (PMVP)

- current quotes and average value forecast:
Stock Quotes pmvpharma.com|PMVP - Price Target Chart
- company stock exchange capitalization indicators:
Market Value PMV Pharmaceuticals|PMVP - Total Company Value
- book capitalization data:
Net Assets per Single Share PMV Pharmaceuticals|PMVP - Company Book Value|Market-to-Book Ratio pmvpharma.com|PMVP - Company Total Assets
- debt level and financial liquidity data:
Debt to Capital Ratio PMV Pharmaceuticals|PMVP - Long-Term Debt to Equity Ratio|Current Liabilities to Capital PMV Pharmaceuticals, Inc|PMVP - Company Total Debt|Debt to Net Assets Ratio PMV Pharmaceuticals|PMVP - Company Long-Term Liabilities|Amount of Current Liabilities PMV Pharmaceuticals|Quick Ratio pmvpharma.com
- net income and valuation multiples indicators:
PMVP - Company Net Income
Fundamental company valuation:pmvpharma.com
Core merchandise of PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals (PMVP) is strengthening its market position by integrating ESG standards into the development of targeted molecules, which requires significant capital expenditures in safe biotechnologies. The total volume of obligations with a maturity of over one year, reflected in the company's long-term debt history, allows for an assessment of credit load sustainability and the risk of capital freeze amid interest rate volatility.

Competitor analysis for PMV Pharmaceuticals

GMAB - Company Long-Term Liabilities|EXEL - Company Long-Term Debt|Long-Term Debt Nuvalent Inc|Kymera Therapeutics Inc (KYMR) - Company Long-Term Debt|IDYA (IDEAYA Corp) - Company Long-Term Debt|Company Long-Term Debt Enliven Therapeutics|Long-Term Debt oricpharma.com ORIC|Company Long-Term Debts RLAY|Nurix Therapeutics Inc (NRIX) - Long-Term Indebtedness|Tyra Bio - Company Long-Term Liabilities|Verastem Corp (VSTM) - Long-Term Debt|GLUE: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings CGEM (cullinanoncology.com)|IMRX (Immuneering) - Company Long-Term Liabilities|CCCC: Amount of Long-Term Liabilities|BDTX (Black Diamond Therapeutics Inc.) - Company Long-Term Debts|Company Long-Term Debts Repare Therapeutics Inc|Company Long-Term Debt Karyopharm Therapeutics (KPTI)|PPCB (propanc.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts BGMS (Bio Green Med Solution)|Long-Term Indebtedness Aadi Bioscience Inc|Aileron - Company Long-Term Debts|Long-Term Debt Blueprint Medicines|GLYC (glycomimetics.com) - Company Long-Term Liabilities|SWTX: Amount of Long-Term Liabilities